Stockreport

Capricor to employ peripheral IV administration of cell therapy CAP-1002 in mid-stage DMD study; shares ahead 13% [Seeking Alpha]

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF Capricor to employ peripheral IV administration of cell therapy CAP-1002 in mid-stage DMD study; shares ahead 13%Capricor Therapeutics (CAPR+12.8%) plans to administer C [Read more]